Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.37 |
| ▸ | PI4KA | P42356 | 1/20 | 0.35 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.35 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.35 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30720840 | 0.95 | HRH3 (0.38) | ALDH1A1PKMHPGDGPR84 | |
| SCHEMBL15778792 | 0.80 | FABP4 (0.31) | — | |
| SCHEMBL4956830 | 0.77 | ALDH1A1 (0.42) | ALDH1A1PKMHPGDGPR84PI4KA | |
| SCHEMBL30720841 | 0.77 | FABP4 (0.30) | — | |
| SCHEMBL5897906 | 0.74 | ALDH1A1 (0.43) | ALDH1A1PKMHPGDGPR84KCNH2 | |
| SCHEMBL1063754 | 0.74 | KCNH2 (0.47) | ALDH1A1PKMHPGDGPR84PI4KA | |
| SCHEMBL24880067 | 0.73 | ALDH1A1 (0.46) | ALDH1A1PKMHPGDGPR84KCNH2 | |
| SCHEMBL6060906 | 0.73 | ALDH1A1 (0.42) | ALDH1A1PKMHPGDGPR84PI4KA | |
| SCHEMBL730079 | 0.73 | KCNH2 (0.50) | ALDH1A1PKMHPGDGPR84KCNH2 | |
| SCHEMBL83498 | 0.73 | ALDH1A1 (0.46) | ALDH1A1PKMHPGDGPR84KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030144-B2 | Substituted imidazole derivatives: GABAA receptor ligands | NEUROGEN CORPORATION (US) | 2006-04-18 | — | — | US | disclosed |
| EP-1499608-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVES: GABA A RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2005-01-26 | — | — | EP | disclosed |
| US-20040002608-A1 | Substituted imidazole derivatives: GABAA receptor ligands | NEUROGEN CORPORATION | 2004-01-01 | — | — | US | disclosed |
| WO-2003093263-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVES: GABAA RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2003-11-13 | — | — | WO | disclosed |
| EP-0991638-A1 | NOVEL GUANIDINE MIMICS AS FACTOR Xa INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2000-04-12 | — | — | EP | disclosed |
| WO-1998057951-A1 | NOVEL GUANIDINE MIMICS AS FACTOR Xa INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-12-23 | — | — | WO | disclosed |
| US-4179512-A | XANTHINE OXIDASE INHIBITORS, HYPOTENSIVE | MERCK & CO., INC. (US) | 1979-12-18 | — | — | US | disclosed |
| US-4110456-A | ANTIHYPERTENSIVE | MERCK & CO., INC. (US) | 1978-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002608-A1 | Substituted imidazole derivatives: GABAA receptor ligands | GABRA1, GABRA3, GABRA2 | ALDH1A1 719/4885PKM 1540/4885HPGD 2526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.